This was followed by another prospective interventional study of 59 patients with a clinical diagnosis of hypertensive nephropathy, all treated with regimens including an angiotensin-converting enzyme (ACE) inhibitor, who had an eGFR 20–59 mL/min/1.73 m2 and a serum bicarbonate <22 mEq/L [64]. Here, ACE is linked to hypertensive nephropathy.